1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Opportunity Analyzer: Vasculitis - Opportunity Analysis and Forecast to 2024

Opportunity Analyzer: Vasculitis - Opportunity Analysis and Forecast to 2024

Summary

Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Behçet's disease (BD). In 2014, there were 137,603 and 82,454 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan), respectively. Untreated, the organs and tissues affected by the damaged blood vessels do not get enough blood, which can lead to organ or tissue damage, or even death. J&J's Remicade was the first biologic in the vasculitis market, approved for BD in Japan in 2007. Other biologics approved for vasculitis include AbbVie's Humira for BD in Japan and Biogen/Roche's Rituxan for GPA/MPA in the 7MM. Several unmet needs still remain such as the development of drugs with improved safety and efficacy for use in both the induction and maintenance treatment settings . GlobalData expects the launch of six drugs during the 2014 to 2024 forecast period along with increased diagnosed patient numbers will drive the vasculitis market.

Highlights

Key Questions Answered

- How large an impact will biosimilars have on the vasculitis market? What do vasculitis specialists and key opinion leaders across the 7MM think about the evolving treatment landscape?
- What opportunities remain in the market for new product entrants?
- With six drug launches, five of which are biologics, which products are forecast to generate the highest sales over 2014-2024? How are product launches expected to affect the sales of induction and maintenance therapies?
- According to KOLs, what are the most important unmet needs in vasculitis? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?
- What industry developments are likely to affect sales of the top-selling vasculitis drugs in the markets researched? Which is the largest growth market globally?

Key Findings

- Biosimilars are expected to change the landscape for vasculitis and create pricing pressure in the vasculitis market. However, questions from physicians and regulators regarding the appropriate use of biosimilars still lingers.
- Sales of immunosuppressants are expected to decline due to the introduction of novel biologics and small molecules to treat vasculitis.
- Several unmet needs are expected to remain after the forecast period, as all pipeline drugs are in development as induction therapies and maintenance therapies are lagging.
- With several major pharmaceutical companies involved in development of vasculitis products, the market will be dominated by Big Pharma who will leverage their R&D, manufacturing, and distribution networks.

Scope

- Overview of vasculitis, including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
- Annualized vasculitis market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the vasculitis market.
- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically BMS’s Orencia, GSK’s Benlysta and Nucala, Genentech/Roche’s Actemra, Celgene’s Otezla, J&J’s Remicade, and biosimilars (such as Celltrion/Hospira/Alvogen’s Inflectra/Remsima).
- Analysis of the current and future market competition in the global vasculitis market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the vasculitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global vasculitis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global vasculitis market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

Opportunity Analyzer: Vasculitis - Opportunity Analysis and Forecast to 2024
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 19
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 21
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Types of Vasculitis 22
3.2 Etiology and Pathophysiology 23
3.2.1 Large Vessel Vasculitis 23
3.2.2 Kawasaki Disease 24
3.2.3 ANCA-Associated Small Vessel Vasculitis 25
3.2.4 Beh?et's Disease 26
3.3 Symptoms 26
3.4 Disease Management 27
3.4.1 Classification Criteria 27
3.4.2 Disease Management Guidelines 28
4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and Comorbidities 35
4.3 Global Trends 36
4.4 Forecast Methodology 39
4.4.1 Sources Used 41
4.4.2 Sources Not Used 61
4.4.3 Forecast Assumptions and Methods 61
4.5 Epidemiological Forecast for Vasculitis, 2014-2024 85
4.5.1 Diagnosed Incident Cases of AAV 85
4.5.2 Diagnosed Prevalent Cases of AAV 87
4.5.3 Age-Standardized Incidence of AAV 89
4.5.4 Diagnosed Incident Cases of LVV - TA and GCA 92
4.5.5 Diagnosed Prevalent Cases of TA 94
4.5.6 Age-Standardized Incidence of LVV 96
4.5.7 Diagnosed Incident Cases of BD 98
4.5.8 Diagnosed Prevalent Cases of BD 100
4.5.9 Age-Standardized Incidence of BD 102
4.5.10 Diagnosed Incident Cases of KD 103
4.6 Discussion 105
4.6.1 Epidemiological Forecast Insight 105
4.6.2 Limitations of the Analysis 106
4.6.3 Strengths of the Analysis 107
5 Current Treatment Options 109
5.1 Overview 109
5.2 Product Profiles 111
5.2.1 Rituxan (Rituximab) 111
5.2.2 Humira (Adalimumab) 115
5.2.3 Remicade (Infliximab) 120
5.2.4 Mycophenolate Mofetil 125
5.2.5 Cyclophosphamide 129
5.2.6 Azathioprine 133
5.2.7 Methotrexate 137
5.2.8 Glucocorticoids 140
5.2.9 Intravenous Immunoglobulin 143
6 Unmet Needs Assessment and Opportunity Analysis 147
6.1 Overview 147
6.2 Improved Drug Efficacy and Safety in the Induction Therapy Setting 148
6.2.1 Unmet Need 148
6.2.2 Gap Analysis 149
6.2.3 Opportunity 151
6.3 Improved Drug Efficacy and Safety in the Maintenance Therapy Setting 151
6.3.1 Unmet Need 151
6.3.2 Gap Analysis 152
6.3.3 Opportunity 153
6.4 Biomarkers to Predict Responsiveness to Therapy 154
6.4.1 Unmet Need 154
6.4.2 Gap Analysis 154
6.4.3 Opportunity 154
6.5 Biomarkers to Predict Disease Relapse 155
6.5.1 Unmet Need 155
6.5.2 Gap Analysis 155
6.5.3 Opportunity 156
6.6 Early and Non-invasive Diagnosis of Vasculitis 156
6.6.1 Unmet Need 156
6.6.2 Gap Analysis 157
6.6.3 Opportunity 158
6.7 Adjunctive Therapy for the Treatment of KD 158
6.7.1 Unmet Need 158
6.7.2 Gap Analysis 160
6.7.3 Opportunity 161
7 RandD Strategies 163
7.1 Overview 163
7.2 Expansion for Key Autoimmune Drugs 163
7.3 Shift Towards Vasculitis as a Primary Indication 164
7.4 Clinical Trial Design 165
7.4.1 Current Clinical Trial Design 166
7.4.2 Challenges in Vasculitis Clinical Trial Design 169
8 Pipeline Assessment 171
8.1 Overview 171
8.2 Promising Drugs in Clinical Development 171
8.2.1 Orencia (Abatacept) 172
8.2.2 Benlysta (Belimumab) 176
8.2.3 Actemra (Tocilizumab) 180
8.2.4 Otezla (Apremilast) 184
8.2.5 Nucala (Mepolizumab) 188
8.3 Additional Drugs in Development for Vasculitis 192
9 Pipeline Valuation Analysis 195
9.1 Clinical Benchmark of Key Pipeline Drugs 195
9.1.1 AAV 195
9.1.2 LVV 196
9.1.3 KD 196
9.1.4 BD 197
9.2 Commercial Benchmark of Key Pipeline Drugs 198
9.2.1 AAV 198
9.2.2 LVV 199
9.2.3 KD 199
9.2.4 BD 200
9.3 Competitive Assessment 202
9.3.1 AAV 202
9.3.2 LVV 203
9.3.3 KD 204
9.3.4 BD 204
9.4 Top Line Ten Year Forecast 205
9.4.1 US 210
9.4.2 5EU 212
9.4.3 Japan 213
10 Appendix 215
10.1 Bibliography 215
10.2 Abbreviations 234
10.3 Methodology 240
10.4 Forecasting Methodology 240
10.4.1 Percent Drug-treated Patients 240
10.4.2 Drugs Included in Each Therapeutic Class 240
10.4.3 Launch and Patent Expiry Dates 241
10.4.4 General Pricing Assumptions 242
10.4.5 Individual Drug Assumptions 243
10.4.6 Generic Erosion 251
10.4.7 Pricing of Pipeline Agents 251
10.5 Primary Research 252
10.5.1 Physicians and Specialists Included in this Study 252
10.5.2 Online Survey of High Prescribing Physicians 253
10.6 About the Authors 254
10.6.1 Author 254
10.6.2 Reviewer 254
10.6.3 Epidemiologist 255
10.6.4 Global Director of Therapy Analysis and Epidemiology 255
10.6.5 Global Head of Healthcare 256
10.7 About GlobalData 257
10.8 Disclaimer 257

1.1 List of Tables
Table 1: Symptoms of Selected Types of Vasculitis 27
Table 2: Nine Recommendations for the Management of BD 30
Table 3: Clinical and Laboratory Features of KD 31
Table 4: Risk Factors and Comorbidities for Vasculitis 36
Table 5: 2012 Revised CHCC Definitions of Vasculitides 40
Table 6: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of MPA 41
Table 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MPA 42
Table 8: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GPA 43
Table 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of GPA 44
Table 10: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of eGPA 45
Table 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of eGPA 46
Table 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GCA 47
Table 13: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of TA 48
Table 14: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of TA 49
Table 15: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of BD 50
Table 16: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of BD 51
Table 17: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of KD 52
Table 18: 7MM, Sources Not Used in Epidemiological Analysis of AAV, LVV, BD, and KD 61
Table 19: 7MM, Diagnosed Incident Cases of AAV, Ages ?15 Years, Both Sexes, N, 2014-2024 86
Table 20: 7MM, Diagnosed Prevalent Cases of AAV, Ages ?15 Years, Both Sexes, N, 2014-2024 88
Table 21: 7MM, Diagnosed Incident Cases of LVV, Ages ?15 Years, Both Sexes, N, 2014-2024 93
Table 22: 7MM, Diagnosed Prevalent Cases of TA, Ages ?15 Years, Both Sexes, N, 2014-2024 95
Table 23: 7MM, Diagnosed Incident Cases of BD, Ages ?15 Years, Both Sexes, N, 2014-2024 99
Table 24: 7MM, Diagnosed Prevalent Cases of BD, Ages ?15 Years, Both Sexes, N, 2014-2024 101
Table 25: 7MM, Diagnosed Incident Cases of KD, Ages ?5 Years, Both Sexes, N, 2014-2024 104
Table 26: Leading Treatments for Vasculitis, 2015 109
Table 27: Current Treatment Options for Vasculitis Across the 7MM, November 2015 111
Table 28: Product Profile - Rituxan 113
Table 29: Rituxan SWOT Analysis, 2015 115
Table 30: Product Profile - Humira 117
Table 31: Humira SWOT Analysis, 2015 120
Table 32: Product Profile - Remicade 122
Table 33: Completed trials demonstrating Remicade as a potential treatment for vasculitis 123
Table 34: Remicade SWOT Analysis, 2015 125
Table 35: Product Profile - Mycophenolate Mofetil 126
Table 36: Evidence for Mycophenolate Mofetil Treatment Therapy in Vasculitis 127
Table 37: MMF SWOT Analysis, 2015 129
Table 38: Product Profile - CYC 130
Table 39: Evidence for cyclophosphamide treatment therapy in vasculitis 131
Table 40: CYC SWOT Analysis, 2014 132
Table 41: Product Profile - Azathioprine 134
Table 42: Evidence for azathioprine treatment therapy in vasculitis 135
Table 43: Azathioprine SWOT Analysis, 2015 137
Table 44: Product Profile - Methotrexate 138
Table 45: Evidence for Methotrexate treatment therapy in vasculitis 139
Table 46: Methotrexate SWOT Analysis, 2015 140
Table 47: Product Profile - Glucocorticoids 141
Table 48: Evidence for Glucocorticoid Treatment Therapy in Vasculitis 142
Table 49: GC SWOT Analysis, 2015 143
Table 50: Product Profile - Intravenous Immunoglobulin 144
Table 51: Evidence for Intravenous Immunoglobulin Therapy in Vasculitis 145
Table 52: GC SWOT Analysis, 2015 146
Table 53: Unmet Need and Opportunity in Vasculitis, 2015 148
Table 54: Vasculitis - Late Stage Pipeline, December 2015 172
Table 55: Product Profile - Orencia 174
Table 56: Orencia SWOT Analysis, 2015 176
Table 57: Product Profile - Benlysta 178
Table 58: Benlysta SWOT Analysis, 2015 179
Table 59: Product Profile - Actemra 181
Table 60: Clinical Trials Demonstrating Actemra as a Potential Treatment for Vasculitis 182
Table 61: Actemra SWOT Analysis, 2015 184
Table 62: Product Profile - Otezla 186
Table 63: Otezla SWOT Analysis, 2015 188
Table 64: Product Profile - Nucala 190
Table 65: Completed Trials Demonstrating Nucala as a Potential Treatment for eGPA 191
Table 66: Nucala SWOT Analysis, 2015 192
Table 67: Early-Stage Pipeline Products in Vasculitis, November 2015 194
Table 68: Clinical Benchmark of Key Pipeline Drugs for AAV 196
Table 69: Clinical Benchmark of Key Pipeline Drugs for LVV, KD, and BD 197
Table 70: Commercial Benchmark of Key Pipeline Drugs for AAV 199
Table 71: Commercial Benchmark of Key Pipeline Drugs for LVV, KD, and BD 201
Table 72: Top-Line Sales Forecasts ($m) for Vasculitis, 2014-2024 206
Table 73: Key Events Impacting Sales for Vasculitis, 2014-2024 209
Table 74: Global Vasculitis Disease Market - Drivers and Barriers, 2014-2024 210
Table 75: Key Launch Dates 241
Table 76: Key Patent Expiries 241
Table 77: Average Body Weight and Surface Area Across the 7MM 243
Table 78: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 253

1.2 List of Figures
Figure 1: Classification of Systemic Vasculitides as Defined by CHCC 2012 23
Figure 2: 7MM, Diagnosed Incident Cases of AAV, Ages ?15 Years, Both Sexes, N, 2014-2024 87
Figure 3: 7MM, Diagnosed Prevalent Cases of AAV, Ages ?15 Years, Both Sexes, N, 2014-2024 89
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of MPA, Ages ?15 Years, Both Sexes, N, 2014 90
Figure 5: 7MM, Age-Standardized Diagnosed Incidence of GPA, Ages ?15 Years, Both Sexes, N, 2014 91
Figure 6: 7MM, Age-Standardized Incidence of eGPA, Ages ?15 Years, Both Sexes, N, 2014 92
Figure 7: 7MM, Diagnosed Incident Cases of LVV, Ages ?15 Years, Both Sexes, N, 2014-2024 94
Figure 8: 7MM, Diagnosed Prevalent Cases of TA, Ages ?15 Years, Both Sexes, N, 2014-2024 96
Figure 9: 7MM, Age-Standardized Diagnosed Incidence of GCA, Ages ?15 Years, Both Sexes, N, 2014 97
Figure 10: 7MM, Age-Standardized Diagnosed Incidence of TA, Ages ?15 Years, Both Sexes, N, 2014 98
Figure 11: 7MM, Diagnosed Incident Cases of BD, Ages ?15 Years, Both Sexes, N, 2014-2024 100
Figure 12: 7MM, Diagnosed Prevalent Cases of BD, Ages ?15 Years, Both Sexes, N, 2014-2024 102
Figure 13: 7MM, Age-Standardized Incidence of BD, Ages ?15 Years, Both Sexes, N, 2014 103
Figure 14: 7MM, Diagnosed Incident Cases of KD, Ages ?5 Years, Both Sexes, N, 2014-2024 105
Figure 15: Competitive Assessment of AAV Pipeline Therapies, 2014-2024 202
Figure 16: Competitive Assessment of LVV, KD, and BD Pipeline Therapies, 2014-2024 203
Figure 17: Global Sales for Vasculitis by Region, 2014-2024 207
Figure 18: Global Sales for Vasculitis by Indication, 2014-2024 208

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based ...

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Pathology Statistics in France

  • November 2016
    2 pages
  • Pathology  

  • France  

    Europe  

    United States  

View report >

Influenza Statistics in the US

  • November 2016
    7 pages
  • Influenza  

    Influenza Vacci...  

    Vaccine  

  • United States  

View report >

Related Market Segments :

Autoimmune Disease
Therapy
Epidemiology

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.